Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InterMune Files NDA For IPF Drug Despite Mixed Pivotal Trial Results

This article was originally published in The Pink Sheet Daily

Executive Summary

With IPF currently an unmet medical need in the U.S.; company seeks priority review; drug marketed in Japan by partner Shionogi.

You may also be interested in...



InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results

FDA has granted the drug priority review status due to the unmet medical need it addresses.

InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results

FDA has granted the drug priority review status due to the unmet medical need it addresses.

China Could Be Third Entry For Idiopathic Pulmonary Fibrosis Drug Pirfenidone

SHANGHAI - Tokyo-headquartered GNI announced its Shanghai-based subsidiary-Shanghai Genomics has submitted a new drug application to Shanghai FDA for its TNF modulator F647 (pirfenidone) to treat patients with idiopathic pulmonary fibrosis (IPF)

Topics

Latest News
UsernamePublicRestriction

Register

PS068829

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel